P. Westveer

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

H. Goldschmidt, P. Sonneveld, H. Lokhorst, 2004, Leukemia.

Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML

G. Peters, P. Sonneveld, W. Graveland, 2002 .

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

W. M. Smit, M. Kersten, P. Sonneveld, 2008, Blood.

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

G. Peters, P. Sonneveld, W. Graveland, 2004, Blood.

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.

P. Sonneveld, B. van der Holt, M. V. van Oers, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

W. M. Smit, B. van der Holt, G. Verhoef, 2006, Annals of Hematology.

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Haematologica.

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

H. Goldschmidt, P. Sonneveld, A. Glasmacher, 2003, Annals of Hematology.

HOVON 50/GMMG-HD3-trial: Phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years.

H. Goldschmidt, P. Sonneveld, E. Vellenga, 2005 .

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

P. Sonneveld, B. van der Holt, G. Verhoef, 2007, British journal of haematology.